Outcomes from the ASPEN intervention program: a randomized clinical trial of a culturally adapted parent-mediated intervention program in low-resource settings
Burnout and perceived health in medical residents after the COVID-19 pandemic: a single-center cross-sectional study
Diagnosis of prolonged grief disorder among older adults: mapping physicians’ knowledge and practice, and evaluating the effectiveness of a brief targeted training program
Diversity of words and words for diversity
Optimized R2 retroelement complexes for DNA insertion into plant genomes
Nature Biotechnology, Published online: 19 June 2026; doi:10.1038/s41587-026-03197-y
R2 retrotransposons are used to integrate DNA into plant and crop 25S ribosomal DNA sites.
Efficient site-specific gene addition using R2 retrotransposons in tobacco and rice
Nature Biotechnology, Published online: 19 June 2026; doi:10.1038/s41587-026-03181-6
Retrotransposons are applied in plants for safe-harbor transgene integration.
Voltage dynamics of cortical dendrites in vivo
Nature Neuroscience, Published online: 19 June 2026; doi:10.1038/s41593-026-02339-4
Simultaneous voltage imaging of soma and dendrites in layer 2/3 cortical neurons in live mice reveals rich dynamics of spike back-propagation, with amplitude shaped by spiking history, dendrite location and behavioral state.
A fatty acid amide activates myeloid cells and improves neurovascular outcomes in retinal degeneration
Nature Neuroscience, Published online: 19 June 2026; doi:10.1038/s41593-026-02341-w
Erucamide, a fatty acid amide reduced in degenerating retinas, activates myeloid cells via TMEM19 to release neurotrophic and angiogenic factors, rescuing photoreceptors and vasculature in mouse models of retinal degeneration.
Tryptamine from wake-active monoaminergic neurons regulates sleep homeostasis
Nature Neuroscience, Published online: 19 June 2026; doi:10.1038/s41593-026-02332-x
Cao et al. identify tryptamine as a sleep signal in mice. Wake-active monoaminergic neurons release tryptamine, which binds to GPR139 in POA neurons that suppress wake-promoting neurons. GPR139 agonists could be a new class of sleep medication.

